electroCore, Inc.

As of May 14, 2019, electroCore, Inc. is considered risky and overvalued due to a high Price to Book Value of 9.74, negative EV to EBIT and EV to EBITDA ratios, and a significantly negative Return on Equity of -280.30%, while its stock has underperformed the S&P 500 with a year-to-date return of -69.19%.

As of May 14, 2019, electroCore, Inc. is considered risky and overvalued due to negative earnings metrics, a high price-to-book ratio of 9.74, an EV to EBITDA ratio of -3.20, and a staggering ROE of -280.30%, with a year-to-date stock performance of -68.35%, significantly underperforming the S&P 500.

As of June 18, 2025, electroCore, Inc. shows a mildly bearish trend, with bearish indicators from MACD, moving averages, and Bollinger Bands, despite mixed signals from the KST.

As of March 2022, the management team of electroCore, Inc. includes Independent Chairman Mr. Michael Atieh, CEO and Director Mr. Daniel Goldberger, Directors Mr. Joseph Errico, Mr. Peter Cuneo, Dr. Thomas Errico, Mr. John Gandolfo, and Mr. Trevor Moody. They oversee the company's strategic direction and operations.

ElectroCore, Inc. is a bioelectronic medicine company focused on developing non-invasive vagus nerve stimulation (nVNS) therapy for various medical conditions. As of March 2025, it reported net sales of $7 million and a net loss of $4 million, with a market capitalization of $37.70 million.

As of Jun 18, electroCore, Inc. has a market capitalization of 37.70 million, with net sales of 26.46 million and a net profit of -12.23 million over the latest four quarters. The company reported shareholder's funds of 7.54 million and total assets of 21.62 million as of Dec 24.